ICUI vs. IART, NUVA, NARI, TNDM, XRAY, MMSI, HAE, QDEL, NEOG, and STAA
Should you be buying ICU Medical stock or one of its competitors? The main competitors of ICU Medical include Integra LifeSciences (IART), NuVasive (NUVA), Inari Medical (NARI), Tandem Diabetes Care (TNDM), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), QuidelOrtho (QDEL), Neogen (NEOG), and STAAR Surgical (STAA). These companies are all part of the "medical" sector.
Integra LifeSciences (NASDAQ:IART) and ICU Medical (NASDAQ:ICUI) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.
Integra LifeSciences has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.
Integra LifeSciences has a net margin of 2.63% compared to Integra LifeSciences' net margin of -2.63%. ICU Medical's return on equity of 14.27% beat Integra LifeSciences' return on equity.
84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 96.1% of ICU Medical shares are held by institutional investors. 3.1% of Integra LifeSciences shares are held by company insiders. Comparatively, 6.7% of ICU Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Integra LifeSciences received 53 more outperform votes than ICU Medical when rated by MarketBeat users. However, 64.48% of users gave ICU Medical an outperform vote while only 57.82% of users gave Integra LifeSciences an outperform vote.
Integra LifeSciences has higher earnings, but lower revenue than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, ICU Medical had 4 more articles in the media than Integra LifeSciences. MarketBeat recorded 7 mentions for ICU Medical and 3 mentions for Integra LifeSciences. ICU Medical's average media sentiment score of 1.19 beat Integra LifeSciences' score of 0.88 indicating that Integra LifeSciences is being referred to more favorably in the media.
Integra LifeSciences presently has a consensus price target of $35.00, indicating a potential upside of 13.27%. ICU Medical has a consensus price target of $123.00, indicating a potential upside of 15.67%. Given Integra LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe ICU Medical is more favorable than Integra LifeSciences.
Summary
Integra LifeSciences beats ICU Medical on 11 of the 18 factors compared between the two stocks.
Get ICU Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICUI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICUI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ICU Medical Competitors List
Related Companies and Tools